Gang Zeng, Ph.D.

July 17, 2015

Doctor Zeng is investigating new biomarkers that could detect the difference between prostate cancer and other prostate abnormalities that are non-malignant. The research will hopefully yield a molecular tool that would complement the prostate-specific antigen (PSA) test given to detect prostate cancer early, minimizing false positives and negatives.

Tags: